RBC Capital Reiterates Outperform on Edwards Lifesciences, Maintains $100 Price Target

Benzinga Newsdesk www.benzinga.com Negative 75.2%

Neg 75.2% Neu 0% Pos 0%

RBC Capital analyst Shagun Singh reiterates Edwards Lifesciences (NYSE:EW) with a Outperform and maintains $100 price target.